◆ Finance
3 Reasons STAA is Risky and 1 Stock to Buy Instead
3 Reasons STAA is Risky and 1 Stock to Buy Instead
Adam Hejl Mon, October 12, 2026 at 1:51 PM EDT 3 min read **
- STAA
- ^GSPC
3 Reasons STAA is Risky and 1 Stock to Buy Instead Over the past six months, STAAR Surgical's shares (currently trading at $21.50) have posted a disappointing 19.9% loss, well below the S&P 500's 12.8% gain. This might have investors contemplating their next move.
Is there a buying opportunity in STAAR Surgical, or does it present a risk to your portfolio? Check out our in-depth research report to see what our analysts have to say, it's free.
Why Do We Think STAAR Surgical Will Underperform?
Despite the more favorable entry price, we're passing on STAAR Surgical for now. Here are three reasons why STAA doesn't excite us, plus one stock we'd rather own.
1. Revenue Growth Flatlining
Long-term growth is the most important, but within healthcare, a stretched historical view may miss new innovations or demand cycles. STAAR Surgical's recent performance shows its demand has slowed as its revenue was flat over the last two years.
Find the leak that's costing you the most money.
Paste a hand history and PokerHack ranks your worst mistakes by $EV lost, then shows the exact GTO fix for each one.
STAAR Surgical Year-On-Year Revenue Growth
2. Fewer Distribution Channels Limit Its Ceiling
Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.
With just $339.6 million in revenue over the past 12 months, STAAR Surgical is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.
3. New Investments Fail to Bear Fruit as ROIC Declines
ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).
Unfortunately, STAAR Surgical's ROIC has decreased significantly over the last few years. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.
STAAR Surgical Trailing 12-Month Return On Invested Capital
Final Judgment
你知道那是一个 hero call。为什么没跟？
STAAR Surgical falls short of our quality standards. Following the recent decline, the stock trades at 22.7× forward P/E (or $21.50 per share). This multiple tells us a lot of good news is priced in - you can find more timely opportunities elsewhere. Let us point you toward a top digital advertising platform riding the creator economy.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks.** The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
** Story Continues Find out which 5 stocks it's flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE**.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
Terms and Privacy Policy [Privacy Dashboard ](https://guce.yahoo.com/privacy-dashboard?